REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early ...

Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twelve analysts that are presently covering the stock, Marketbeat.com reports. One ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Research analysts at Leerink Partnrs boosted their FY2024 earnings per share estimates for shares of REGENXBIO in a report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now ...